Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Windlas Biotech's Enterprise Value is ₹15,308 Mil.
Windlas Biotech's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 was ₹918 Mil. Therefore, Windlas Biotech's EV-to-EBIT ratio for today is 16.67.
EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Windlas Biotech's Enterprise Value is ₹15,308 Mil.
Windlas Biotech's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was ₹1,225 Mil. Therefore, Windlas Biotech's EV-to-EBITDA ratio for today is 12.49.
EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, Windlas Biotech's Enterprise Value is ₹15,308 Mil.
Windlas Biotech's Revenue for the trailing twelve months (TTM) ended in Mar. 2026 was ₹9,041 Mil. Therefore, Windlas Biotech's EV-to-Revenue ratio for today is 1.69.
*** Please note that the current Enterprise Value is calculated using the current market capitalization and the most recently available financial data. If key financial fields—Long-Term Debt & Capital Lease Obligation and Short-Term Debt & Capital Lease Obligation—are recorded as null in the latest reporting period, our data vendor will default to using data from the prior period with valid entries.
Windlas Biotech (NSE:WINDLAS) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
Windlas Biotech's current Enterprise Value is ₹15,308 Mil.
Windlas Biotech's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹918 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
Windlas Biotech's current Enterprise Value is ₹15,308 Mil.
Windlas Biotech's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹1,225 Mil.
Windlas Biotech's current Enterprise Value is ₹15,308 Mil.
Windlas Biotech's Revenue for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹9,041 Mil.
Windlas Biotech's current Enterprise Value is ₹15,308 Mil.
Windlas Biotech's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹0 Mil.
Windlas Biotech's current Enterprise Value is ₹15,308 Mil.
Windlas Biotech's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹0 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Windlas Biotech Enterprise Value Related Terms
Windlas Biotech Enterprise Value Historical Data
* Premium members only.
The historical data trend for Windlas Biotech's Enterprise Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:WINDLAS vs ZTS, UTHR: Enterprise Value Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Windlas Biotech's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Windlas Biotech Enterprise Value vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Windlas Biotech's Enterprise Value distribution charts can be found below:
* The bar in red indicates where Windlas Biotech's Enterprise Value falls into.
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
Windlas Biotech's Enterprise Value for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Windlas Biotech (NSE:WINDLAS) has a Enterprise Value of ₹15,308 Mil as of Jun. 29, 2026. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Windlas Biotech and its competitors.
Is Windlas Biotech's Enterprise Value too high?
Windlas Biotech's current Enterprise Value is ₹15,308 Mil. Overall, Windlas Biotech has a GF Score™ of 86/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Windlas Biotech's Enterprise Value compare to ZTS and UTHR?
Windlas Biotech's Enterprise Value of ₹15,308 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Enterprise Value for a Drug Manufacturers company?
A good Enterprise Value depends on the Drug Manufacturers industry context. However, Enterprise Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Enterprise Value mean?
A high Enterprise Value can signal that a stock is expensive relative to its fundamentals. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Windlas Biotech and its competitors. Windlas Biotech's current Enterprise Value is ₹15,308 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Windlas Biotech stock overvalued right now?
Based on GuruFocus' analysis, Windlas Biotech (NSE:WINDLAS) is currently considered Fairly Valued. The stock's GF Value™ is ₹936.98, compared to a current price of ₹859.00 — trading 8.3% below its estimated fair value. The current Enterprise Value is ₹15,308 Mil. Windlas Biotech's overall GF Score™ is 86/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Enterprise Value calculated?
Enterprise Value is calculated from a company's financial statements. For Windlas Biotech (NSE:WINDLAS), the current Enterprise Value is ₹15,308 Mil as of Jun. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Windlas Biotech (NSE:WINDLAS) Overvalued in 2026?
Based on GuruFocus' analysis, Windlas Biotech stock appears to be undervalued.
The current stock price of ₹859.00 is trading 8.3% below its estimated GF Value™ of ₹936.98.
GuruFocus considers Windlas Biotech to be Fairly Valued.
Key valuation signals for NSE:WINDLAS:
Enterprise Value: ₹15,308 Mil
GF Value™: ₹936.98 vs. price of ₹859.00 (8.3% below fair value)
No single metric tells the full story. See the NSE:WINDLAS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Windlas Biotech Ltd is a pharmaceutical formulation contract development and manufacturing organization. The company offers a range of CDMO services from product discovery to product development, licensing, and commercial manufacturing of generic products including complex generics.
86GF Score
Get the complete analysis for NSE:WINDLAS
Enterprise Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:WINDLAS has been successfully added to your 
